Orem, UT

Andrea Johnson

Andes Clinical Research

Major Depressive Disorder

GATE-251

Syndeio Biosciences, Inc

condition

allSponsorName

Worldwide Clinical Trials

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The goal of this clinical trial is to learn if zelquistinel works to treat depression in adults. It will also learn about the safety of zelquistinel. The main questions it aims to answer are:

Does zelquistinel reduce depression scores in participants compared to participants who take a placebo (a look-alike tablet that contains no zelquistinel)?

What medical problems are observed in participants who take zelquistinel?

Participants will take one tablet of zelquistinel or placebo every week for 6 weeks. Participants will visit the clinic every week of the 6 week period to have the severity of their depression evaluated.

Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

Andes Clinical Research | Orem, UT

Site insights

Contact this site

Active trials

Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder (GATE-251)

Trial sponsors